Results 151 to 160 of about 135,038 (281)

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Mitigation of Metabolic Diseases Through Personalized Nutrition: A Critical In-Depth Review. [PDF]

Food Sci Nutr
Arshad MT, Ali MKM, Awlqadr FH, Maqsood S, Ikram A, Hossain MS, Abdullahi MA, Rashed MM.   +7 more
europepmc   +1 more source

Long‐term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real‐world cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aim Elexacaftor/tezacaftor/ivacaftor (ETI) has markedly improved cystic fibrosis (CF) outcomes. However, its long‐term impact on nutrition, metabolism and liver health remains underexplored. We assessed 30‐month changes in pulmonary, nutritional, metabolic and inflammatory markers in people with CF (PwCF) homozygous for F508del.
Nicola Perrotta, Luigi Angelo Fiorito, Roberta Vescovo, Anna Virgilio, Giulia Amato, Giuseppe Cimino   +5 more
wiley   +1 more source

The evolving therapeutic landscape of spinal muscular atrophy – A scoping review of investigational agents, emerging delivery technologies and strategic innovations

British Journal of Clinical Pharmacology, EarlyView.
Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić, Patrick Eustaquio, Elvira Meni Maria Gkrinia, Ivana Stević, Eugen Javor, Yun Wah Lam, Slobodan Janković, Dinko Vitezić   +7 more
wiley   +1 more source

Integrated omics approaches with non-thermal food fortification: pathways to personalized nutrition solutions. [PDF]

Front Nutr
Alsanie SA.
europepmc   +1 more source

Harnessing Cellular Feeling: Epigenetic to Mechanical Memory as a Framework for Stem Cell Manufacturing

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Stem cell‐based therapies hold transformative potential for regenerative medicine, yet their progress is constrained by persistent variability in manufacturing and clinical performance. Conventional frameworks such as Quality by Design (QbD), though effective for drugs and biologics, struggle to accommodate the dynamic nature of living cell ...
Mee‐Hae Kim, Masahiro Kino‐oka
wiley   +1 more source

Continuous Glucose Monitoring for Personalized Nutrition in Real-World Vively App Users: Retrospective Observational Study. [PDF]

JMIR Hum Factors
Jospe MR, Richardson KM, Schembre SM.
europepmc   +1 more source

Personalized Nutrition Through the Gut Microbiome in Metabolic Syndrome and Related Comorbidities. [PDF]

Nutrients
Plaza-Diaz J, Herrera-Quintana L, Olivares-Arancibia J, Vázquez-Lorente H.   +3 more
europepmc   +1 more source

New opportunities for bioscaffold‐enabled spinal cord injury repair

BMEMat, EarlyView.
Schematic illustration of bioscaffolds for spinal cord injury repair. We summarize the effects of bioscaffold properties on SCI repair, highlight different types of bioscaffolds, various fabrication strategies, and in vivo transformations for the clinical development of SCI‐repairing bioscaffolds.
Xiaoqing Qi, Yicheng Fu, Zhaoliang Su, Li Li, Subrata Chakrabarti, Peng Li, Yilun Wu, Fang Liu, Teng Gao, Zhifeng Dong, Lei Liu, Pei Cao   +11 more
wiley   +1 more source

Personalized Nutrition Recommendations Using a Bayesian Mixture Model of Concentration Constraints and Intake Preferences. [PDF]

Stat Med
Turkia J, Schwab U, Hautamäki V.
europepmc   +1 more source